NEW YORK (GenomeWeb) – Diagnostics firm Protagen announced a long-term collaboration agreement with Qiagen to provide pharmaceutical partners access to technology that would advance the development of protein-based companion tests for autoimmune disorders.

The terms of the agreement give Qiagen access to Protagen's proprietary SeroTag, an automated multiplex technology that can facilitate the discovery and validation of protein-based biomarker panels. SeroTag can measure autoantibody levels for thousands of antigens from a patient's single serum sample.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.